Trial Profile
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms TULIP 2
- Sponsors AstraZeneca; AstraZeneca AB
- 03 Jun 2023 Results (n=369) assessing the long-term impact of anifrolumab compared with placebo on Lupus Low Disease Activity State attainment over the 1 year TULIP-1/TULIP-2 (NCT02446912, NCT02446899) and 3 year long-term extension (NCT02794285) study periods, presented at the 24th Annual Congress of the European League Against Rheumatism.
- 23 Jan 2023 Results of post-hoc pooled analysis of two studies (NCT02446912 and NCT02446899) assessing lupus low disease activity state (LLDAS) attainment in anifrolumab-treated patients were published in the Annals of the Rheumatic Diseases.
- 14 Nov 2022 Results assessing to identify biomarkers associated with anifrolumab treatment using transcriptomic assessments of longitudinal whole blood samples from phase 3 TULIP-1 and TULIP-2 trials, presented at the ACR Convergence 2022.